Published June 2008 | Version v1
Journal article Metadata-only

Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: Long-term results of a placebo-controlled randomised study

Creators

  • 1. Department of Radiology, Tokyo Metropolitan Komagome Hospital (Japan)
  • 2. Department of Surgery, Tohoku University School of Medicine (Japan)
  • 3. Department of Surgery, Tokyo Metropolitan Komagome Hospital (Japan)
  • 4. Department of Radiology, Tohoku University School of Medicine (Japan)
  • 5. Department of Radiation Oncology, Kinki University School of Medicine (Japan)
  • 6. Department of Radiology, Nagoya City University School of Medicine (Japan)

Description

Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p = 0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer

Availability note (English)

Available from http://dx.doi.org/10.1016/j.radonc.2008.02.007

Additional details

Identifiers

DOI
10.1016/j.radonc.2008.02.007;
PII
S0167-8140(08)00101-1;

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
87
Journal Issue
3
Journal Page Range
p. 326-330
ISSN
0167-8140
CODEN
RAONDT

INIS

Country of Publication
Ireland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
40005257
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; EPIDEMIOLOGY; EVALUATION; PANCREAS; RADIOTHERAPY
Descriptors DEC
BODY; DIGESTIVE SYSTEM; DISEASES; ENDOCRINE GLANDS; GLANDS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.